retatrutide fda approval date New Weight Loss Drug Retatrutide: My Patient's 85-Pound Journey (And What the Trials Don't The FDA has issued warning

Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes

Personalized Dosing: The Role of Genetic Testing Not every person responds identically to GLP-1 therapy

No Endorsement of Specific Treatment Outcomes References to clinical trial data, average weight loss outcomes, and efficacy information for GLP-1 medications in this article are drawn from published peer-reviewed research on FDA-approved formulations

The fix is not a higher dose

Food and Drug Administration (FDA) to treat obesity, expanding their use beyond the original purpose of diabetes management, demand for these drugs is skyrocketing and employers are struggling to weigh the high costs of coverage

Navigating the Impending Generics Entry Wegovy generics expected between 20262032 will likely reshape the market, particularly given the large self-pay, cost-sensitive patient base